Ebola Survivors’ Immunity Questioned After Death In DRC; J&J Announces 2nd Ebola Vaccine Set To Launch Soon; WSJ Examines Ebola Treatment Trials In Congo’s Conflict Zones
CIDRAP News: DRC Ebola total rises as South Sudan clash kills screeners
“The Democratic Republic of the Congo (DRC) [Wednesday] reported one new Ebola case, alongside a new report of a security clash in South Sudan that killed three aid workers who were staffing an Ebola screening checkpoint. In other developments, a new assessment from the World Health Organization (WHO) of the outbreak said the incidence of new cases over the past week remained steady, but the movement of patients from the few remaining hot spots still pose a risk of spread to other areas…” (Schnirring, 10/30).
Reuters: Exclusive: WHO, Congo eye tighter rules for Ebola care over immunity concerns
“The World Health Organization and Congolese authorities are proposing changes to how some Ebola patients are cared for, new guidelines show, after a patient’s death challenged the accepted medical theory that survivors are immune to reinfection. There are many unanswered questions surrounding the circumstances of the woman’s death in Democratic Republic of Congo, which has not previously been reported…” (Prentice/Bujakera, 10/31).
STAT: Second Ebola vaccine set to be used soon in Democratic Republic of the Congo
“The Democratic Republic of the Congo will begin using a second Ebola vaccine as early as next week, the company developing the experimental product, Johnson & Johnson (JNJ), said Thursday. J&J announced it is donating enough of the product to vaccinate up to 500,000 people. The vaccine will be used as part of a clinical trial…” (Branswell, 10/31).
Wall Street Journal: ‘Ebola Is Now a Disease We Can Treat.’ How a Cure Emerged From a War Zone.
“…In a medical breakthrough that compares to the use of penicillin for war wounds, two new drugs are saving lives from the virus and helping uncover tools against other deadly infectious diseases. They were proven effective in a gold-standard clinical trial conducted by an international coalition of doctors and researchers in the middle of armed violence…” (McKay, 10/30).